4-Methoxyphencyclidine (methoxydine, 4-MeO-PCP) is a dissociative anesthetic drug that has been sold online as a research chemical. The synthesis of 4-MeO-PCP was first reported in 1965 by the Parke-Davis medicinal chemist Victor Maddox. A 1999 review published by a chemist using the pseudonym John Q. Beagle suggested the potency of 4-MeO-PCP in man was reduced relative to PCP, two years later Beagle published a detailed description of the synthesis and qualitative effects of 4-MeO-PCP, which he said possessed 70% the potency of PCP. 4-MeO-PCP was the first arylcyclohexylamine research chemical to be sold online, it was introduced in late 2008 by a company trading under the name CBAY and was followed by several related compounds such as 3-MeO-PCP and methoxetamine. 4-MeO-PCP has lower affinity for the NMDA receptor than PCP, but higher affinity than ketamine, it is orally active in a dosage range similar to ketamine, with some users requiring doses in excess of 100mg for desired effects. Users have reported substantial differences in active dose, these discrepancies can be partially explained by the presence of unreacted PCC and other impurities in samples sold on the grey market. 4-MeO-PCP has Ki values of 404 nM for the NMDA receptor, 713 nM for the norepinephrine transporter, 844 nM for the serotonin transporter, 296 nM for the σ1 receptor and 143 nM for the σ2 receptor.
4-MeO-PCP hydrochloride is a white crystalline solid with a melting point of 181-182°C
Safety at a Glance
High Risk- It is strongly recommended that one use harm reduction practices when using this drug.
- Urinary tract effects
- Toxicity: The toxicity and long-term health effects of recreational 4-MeO-PCP use do not seem to have been studied in any scien...
- Dangerous with: Acetylfentanyl, Buprenorphine, Codeine, Desomorphine (+15 more)
- Overdose risk: Overdose on 4-MeO-PCP can range from unpleasant to life-threatening depending on the dose, route,...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
insufflated
oral
Duration
insufflated
Total: 12 hrs – 18 hrsoral
Total: 12 hrs – 20 hrsHow It Feels
The onset creeps in with a foggy, sedating heaviness that settles over the mind like a thick wool blanket dropped without warning. Within half an hour the world begins to recede, but not with the crystalline clarity of its methoxy cousins — instead, it simply dims, as though someone is slowly lowering the brightness on every channel of perception simultaneously. Your limbs grow dense and reluctant; the idea of standing up begins to feel like a complex engineering problem rather than an automatic physical act.
As the dissociation deepens, a profound confusion takes root. This is not the conceptual confusion of the psychedelic class — it is structural, affecting the very machinery of thought. Sentences begin normally in your mind and then lose their endings, dissolving into a murk that your attention cannot penetrate. You reach for a word and find nothing there, just a smooth, dark space where meaning should be. Sound becomes distant and muffled, as though the room is slowly filling with an invisible, sound-dampening substance. Other people's speech reaches you as melody without lyrics — you can hear tone, rhythm, and cadence, but the semantic content has been gently removed.
The peak is a place of deep sedation and disorientation. The body has become a distant report — you know it is there, somewhere below you, but its signals arrive scrambled and faint. Gravity seems to have multiplied; even your eyelids feel heavy. Closed-eye space, if you can maintain enough focus to observe it, is dark and amorphous — slow, shapeless movements in deep hues, more felt than seen. There is no euphoria, or very little. The emotional tone is flat and neutral, neither pleasant nor unpleasant, simply absent, as though the circuits responsible for emotional coloring have been temporarily disconnected. Time loses all structure; minutes and hours become indistinguishable.
The comedown is slow and leaves a residual fog that can persist for hours after the dissociation itself has lifted. You may find yourself staring at a wall, unsure of how long you have been doing so. Sleep eventually comes but may be restless, punctuated by strange half-dreams that blend seamlessly with waking confusion. The morning after carries a dull, hungover quality — not painful, but grey, as though the world has been returned to you with slightly reduced resolution.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(8)
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical autonomy— Physical autonomy is the experience of one's body performing actions — from simple tasks like walkin...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Spatial disorientation— Spatial disorientation is the inability to accurately perceive one's position or orientation within ...
Tactile(1)
- Tactile suppression— A progressive decrease in the ability to feel physical touch, ranging from mild numbness to complete...
Cognitive & Perceptual Effects
Visual(11)
- Double vision— The visual experience of seeing a single object as two separate, overlapping images, similar to cros...
- Environmental cubism— A visual distortion in which the environment and objects within it appear fragmented into geometric,...
- Frame rate suppression— Perception of visual motion as choppy discrete frames rather than smooth continuous flow, resembling...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Visual acuity suppression— Vision becomes blurred, indistinct, and out of focus, as though looking through a smudged lens. Fine...
- Visual disconnection— A dissociative visual effect involving a progressive detachment from visual perception, ranging from...
Cognitive(21)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis suppression— Analysis suppression is a cognitive impairment in which the capacity for logical reasoning, critical...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depersonalization— A detachment from one's own sense of self, body, or mental processes, as if observing oneself from o...
- Derealization— A perceptual disturbance in which the external world feels profoundly unreal, dreamlike, or artifici...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Dream potentiation— Enhanced dream vividness, complexity, and recall, often occurring as REM rebound after discontinuing...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
Multi-sensory(1)
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(2)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
Pharmacology
4-MeO-PCP acts as an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “k-hole.”
4-MeO-PCP has lower affinity for the NMDA receptor than PCP, but higher affinity than ketamine. It is orally active in a dosage range similar to ketamine with some users requiring doses in excess of 100mg for desired effects..
Sweden** - Sweden's public health agency suggested classifying 4-MeO-PCP as a hazardous substance on November 10, 2014.
Switzerland:** 4-MeO-PCP is a controlled substance specifically named under Verzeichnis E.
Turkey:** 4-MeO-PCP is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom** - 4-MeO-PCP is a class B drug in the UK and is illegal to possess, produce, supply, or import. As a derivative of 1-Phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group, further substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.
Responsible use
Research chemical
Dissociatives
PCP
4-MeO-PCP (Wikipedia)
4-MeO-PCP (Erowid Vault)
4-MeO-PCP (Isomer Design)
4-MeO-PCP (Bluelight)
Interview with a Ketamine Chemist (VICE)
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
Detection Methods
Standard Drug Panel Inclusion
4-MeO-PCP may or may not trigger a positive result on standard PCP immunoassay screens. The 4-methoxy substitution places the methoxy group at a different position on the phenyl ring compared to 3-MeO-PCP, resulting in different antibody cross-reactivity profiles. Reports suggest variable detection, with some immunoassay platforms producing weak positive results and others returning negative results. A negative standard PCP screen does not exclude 4-MeO-PCP use.
Urine Detection
4-MeO-PCP is detectable in urine for approximately 3 to 7 days after a single dose. The compound is metabolized by O-demethylation and hydroxylation pathways, producing metabolites including 4-HO-PCP. Urine detection requires LC-MS/MS methods that specifically include 4-MeO-PCP and its metabolites in the analytical panel. The lipophilic arylcyclohexylamine structure contributes to tissue accumulation and extended urinary excretion.
Blood and Serum Detection
Blood detection windows are approximately 1 to 3 days. Pharmacokinetic data for 4-MeO-PCP is extremely limited, and concentration ranges associated with impairment or toxicity have not been systematically established. Forensic case reports provide the primary source of blood concentration data.
Hair Follicle Detection
Hair analysis for 4-MeO-PCP is theoretically feasible but has not been widely validated. The compound's basic and lipophilic properties suggest adequate hair incorporation for detection by LC-MS/MS methods.
Confirmatory Methods
LC-MS/MS with appropriate reference standards is required for definitive identification. GC-MS is also applicable. The compound must be specifically targeted, as it will not appear on standard PCP confirmation panels at most laboratories.
Reagent Testing
The Marquis reagent produces minimal or no reaction with 4-MeO-PCP. The Mandelin reagent may yield an orange-brown color. Reagent profiles are similar to other methoxylated PCP analogues and cannot distinguish between individual compounds in the class.
Interactions
| Substance | Status | Note |
|---|---|---|
| Acetylfentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Buprenorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Codeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Desomorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dextropropoxyphene | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dihydrocodeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Ethylmorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Fentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Heroin | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydrocodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydromorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Kratom | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Methadone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Morphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Naloxone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| O-Desmethyltramadol | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxycodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxymorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Pethidine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| 1,4-Butanediol | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 2-Fluorodeschloroketamine | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 2M2B | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 3-Cl-PCP | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-HO-PCE | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 1,3-Butanediol | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1B-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-AL-LAD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-MiPLA | Low Risk & Synergy | Produces unique synergistic effects; often combined |
History
4-MeO-PCP belongs to the dissociative class of substances, a pharmacological category with roots in anesthesiology research. The first dissociative anesthetic, phencyclidine (PCP), was developed in the 1950s by Parke-Davis as a surgical anesthetic. While PCP was effective, its pronounced emergence phenomena (confusion, hallucinations, agitation upon waking) led researchers to develop alternatives with more manageable side effect profiles.
Ketamine, synthesized in 1962, became the most successful clinical dissociative anesthetic and remains in widespread medical use today. The discovery that sub-anesthetic doses of ketamine produce rapid antidepressant effects has driven renewed clinical interest in dissociative compounds.
4-MeO-PCP emerged within this broader landscape of dissociative pharmacology. Novel dissociative compounds continue to be developed by researchers and have appeared in the designer drug market, with varying degrees of resemblance to the established clinical agents.
Harm Reduction
It is strongly recommended that one use harm reduction practices when using this drug.
As with other NMDA receptor antagonists, the chronic use of 4-MeO-moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.
Tolerance to many of the effects of 4-MeO-develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). 4-MeO-PCP presents cross-tolerance with Cross-all dissociatives, meaning that after the consumption of 4-MeO-PCP all dissociatives will have a reduced effect.
- Urinary tract effects
In terms of its long-term health effects when used repeatedly and with excess for extended periods of time, 4-MeO-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within ketamine but to a lesser extent. This is because 4-MeO-PCP is a little more potent than ketamine, meaning that less of the drug needs to be consumed. Symptoms of ketamine-induced cystitis can become extremely serious and can be described as:
- Urinary frequency** - Urinary frequency is the need to empty the bladder every few minutes.
- Urinary urgency** - This can be described as a sudden, compelling need to urinate.
- Urinary pressure** - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
- Pelvic and bladder pain** - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
- Hematuria** - Hematuria is visible blood
Toxicity & Safety
The toxicity and long-term health effects of recreational 4-MeO-PCP use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 4-MeO-PCP has very little history of human usage. Anecdotal evidence from people who have tried 4-MeO-PCP within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
As with other NMDA receptor antagonists, the chronic use of 4-MeO-PCP can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.
Tolerance to many of the effects of 4-MeO-PCP develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 4-MeO-PCP presents cross-tolerance with all dissociatives, meaning that after the consumption of 4-MeO-PCP all dissociatives will have a reduced effect.
Dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Stimulants - Both stimulants and dissociatives carry the risk of adverse psychological reactions like anxiety, mania, delusions and psychosis and these risks are exacerbated when the two substances are combined.
Depressants - Because both depress the respiratory system, this combination can result in an increased risk of suddenly falling unconscious, vomiting and choking to death from the resulting suffocation. If nausea or vomiting occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
Urinary tract effects
In terms of its long-term health effects when used repeatedly and with excess for extended periods of time, 4-MeO-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within ketamine but to a lesser extent. This is because 4-MeO-PCP is a little more potent than ketamine, meaning that less of the drug needs to be consumed. Symptoms of ketamine-induced cystitis can become extremely serious and can be described as:
Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
Urinary urgency - This can be described as a sudden, compelling need to urinate.
Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
Pelvic and bladder pain - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
Hematuria - Hematuria is visible blood in the urine.
Incontinence - This is the leakage of urine. All of these, however, can easily be avoided by simply not using 4-MeO-PCP on a daily or even weekly basis and manually limiting one's usage of the substance.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Overdose on 4-MeO-PCP can range from unpleasant to life-threatening depending on the dose, route, and whether other substances are involved.
Signs of overdose: Severe nystagmus, complete unresponsiveness, vomiting (aspiration risk while unconscious), severely depressed breathing, seizures, extremely elevated heart rate or blood pressure.
Critical dangers:
- Respiratory depression: Particularly when combined with other depressants
- Aspiration: Loss of protective reflexes combined with nausea creates choking risk
- Hyperthermia or hypothermia: Impaired thermoregulation at high doses
Emergency response: Place the person in the recovery position. Monitor breathing. Call emergency services if breathing is slow, shallow, or irregular; if the person is unresponsive to stimulation; or if seizures occur. Be honest with medical personnel about what was consumed — they are there to help, not to judge.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Germany:** 4-MeO-PCP is a controlled substance under the NpSG since 27th September 2021.
Sweden** - Sweden's public health agency suggested classifying 4-MeO-PCP as a hazardous substance on November 10, 2014.
Switzerland:** 4-MeO-PCP is a controlled substance specifically named under Verzeichnis E.
Turkey:** 4-MeO-PCP is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom** - 4-MeO-PCP is a class B drug in the UK and is illegal to possess, produce, supply, or import. As a derivative of 1-Phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group, further substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.
Responsible use
Research chemical
PCP
4-MeO-PCP (Wikipedia)
4-MeO-PCP (Erowid Vault)
4-MeO-PCP (Isomer Design)
4-MeO-PCP (Bluelight)
Interview with a Ketamine Chemist (VICE)
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
Experience Reports (1)
Tips (3)
Choose a safe physical environment before using 4-MeO-PCP. Remove sharp objects, secure stairs, and create a comfortable space to lie or sit. Dissociation makes spatial awareness unreliable and falls are common.
Do not combine 4-MeO-PCP with other CNS depressants (alcohol, opioids, benzodiazepines). Dissociatives already depress breathing and cardiovascular function. Adding other depressants creates dangerous respiratory depression.
Tolerance to 4-MeO-PCP builds with regular use. Taking breaks of at least 1-2 weeks between sessions helps prevent tolerance escalation and reduces the risk of bladder and cognitive damage from frequent use.
See Also
References (3)
- Ketamine as a rapid antidepressant — Berman et al. Biological Psychiatry (2000)paper
- 4-MeO-PCP - TripSit Factsheet
TripSit factsheet for 4-MeO-PCP
tripsit - 4-MeO-PCP - Wikipedia
Wikipedia article on 4-MeO-PCP
wikipedia